Minamoto Tomomi, Parambeth Joseph C, Walzem Rosemary L, Payne Harold R, Lidbury Jonathan A, Suchodolski Jan S, Steiner Jörg M
Gastrointestinal Laboratory, Department of Veterinary Small Animal Clinical Sciences (Minamoto, Parambeth, Lidbury, Suchodolski, and Steiner), Texas A&M University, College Station, TX.
Image Analysis Laboratory, Department of Veterinary Pathobiology (Payne), Texas A&M University, College Station, TX.
J Vet Diagn Invest. 2018 Nov;30(6):878-886. doi: 10.1177/1040638718793677. Epub 2018 Sep 3.
Changes in proportions of lipoprotein classes have been described in disease states in humans. In veterinary medicine, hyperlipidemia can cause complications, such as cutaneous xanthomas, liver disease, cholelithiasis, pancreatitis, glomerular disease, lipemia retinalis, or peripheral neuropathy, but there are few reports regarding lipoproteins in diseased animals. For canine serum, we partially validated continuous lipoprotein density profiling (CLPDP), a novel density gradient ultracentrifugation technique. We examined canine lipoproteins separated by CLPDP by transmission electron microscopy (TEM). We compared lipoprotein profiles between healthy control dogs ( n = 29) and dogs with exocrine pancreatic insufficiency (EPI; n = 28) using CLPDP. Dogs with EPI included those untreated (EPI-NT; n = 6) and those treated with enzyme supplementation (EPI-T; n = 22). Our preliminary assay validation showed that CLPDP was repeatable (CV = 11.2%) and reproducible (CV = 10.6%) in canine serum. The diameters of lipoproteins analyzed by TEM were similar to those reported previously. Dogs in the EPI-NT group had more severe dyslipidemia than dogs in the EPI-T group. Dogs in the EPI-T group had lipoprotein profiles similar to healthy control dogs. CLPDP might be a useful tool for evaluating dyslipidemia in dogs.
人类疾病状态下脂蛋白类比例的变化已有相关描述。在兽医学中，高脂血症可引发并发症，如皮肤黄瘤、肝病、胆石症、胰腺炎、肾小球疾病、视网膜脂血症或周围神经病变，但关于患病动物脂蛋白的报道较少。对于犬血清，我们部分验证了连续脂蛋白密度分析（CLPDP）这一新型密度梯度超速离心技术。我们通过透射电子显微镜（TEM）检查了经CLPDP分离的犬脂蛋白。我们使用CLPDP比较了健康对照犬（n = 29）和患有外分泌性胰腺功能不全（EPI；n = 28）的犬的脂蛋白谱。患有EPI的犬包括未治疗的犬（EPI-NT；n = 6）和接受酶补充治疗的犬（EPI-T；n = 22）。我们的初步分析验证表明，CLPDP在犬血清中具有可重复性（CV = 11.2%）和可再现性（CV = 10.6%）。通过TEM分析的脂蛋白直径与先前报道的相似。EPI-NT组的犬比EPI-T组的犬患有更严重的血脂异常。EPI-T组的犬的脂蛋白谱与健康对照犬相似。CLPDP可能是评估犬血脂异常的有用工具。
